4.50Open4.50Pre Close0 Volume1 Open Interest7.50Strike Price0.00Turnover0.00%IV-87.50%PremiumJan 17, 2025Expiry Date5.90Intrinsic Value100Multiplier23DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma0.30Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Pyxis Oncology Stock Discussion
Pyxis Oncology Announces Portfolio Prioritization, Focusing Resources on its Lead Clinical Program, PYX-201
Thursday, 19th December at 4:08 pm
- The Company will focus resources on advancing its lead asset, PYX-201
- PYX-201 is a novel first-in-concept antibody-drug conjugate (ADC) where significant RECIST responses were seen in head and neck squamous cell carcinoma (HNSCC) with additional potential in other solid tumors
- Current cash runway expected to fund devel...
📊⚡️📊
$Applied Therapeutics (APLT.US)$ Crashed after FDA CRL but will resubmit. Dropped from 10 to 1.3 rebounded to 1.95. SI 16%
$PainReform (PRFX.US)$ Microfloat. Up after hours. SI 20%. 0 shares LTB. CTB 436%. If there is no catalyst, microfloats will be a quick play.✔️
$Blue Ocean Acquisition Corp(Delisted) (BOCN.US)$ Merger ...
This is the PYXS entire press release from its website
pyxisoncology.c...
Pyxis Oncology Announces Favorable Preliminary PYX-201 Clinical Phase 1 Part 1 Data
PDF Version
— PYX-201 achieved a confirmed 50% ORR by RECIST 1.1 including one Complete Response and 100% Disease Control Rate in six heavily pretreated HNSCC patients, supporting differentiated mono and front-line combo ther...
No comment yet